Variable | Hazard ratio (95% CI) | p |
---|---|---|
ANCA at switching to maintenance therapy | ||
ANCA-positive | 1 | 0.004 |
ANCA-negative | 0.57 (0.38–0.84) | |
ANCA at trial entry | ||
MPO-ANCA | 1 | 0.002 |
PR3-ANCA | 1.99 (1.30–3.04) | |
Patient age (per decade) | 0.79 (0.70–0.90) | <0.001 |
Serum creatinine at entry (per 50 μmol/L) | 0.87 (0.80–0.95) | 0.002 |
Clinical diagnosis | ||
GPA | 1 | 0.002 |
MPA | 0.72 (0.59–0.89) | |
Initial induction treatment | ||
Daily oral cyclophosphamide | 1 | 0.016 |
Pulsed cyclophosphamide | 1.64 (1.10–2.45) | |
Initial maintenance therapy | ||
AZA | 1 | <0.001 |
MMF | 2.13 (1.42–3.19) | |
Time to remission (per month) | 1.07 (0.95–1.21) | 0.279 |